Earlier this month, at the American Society of Clinical Oncology annual meeting in Chicago, Onconova presented interim data from its Phase II ONTARGET study testing oral rigosertib as a single agent in transfusion-dependent, lower risk MDS patients...The company also reported 20.6 million shares of common stock outstanding as of March 31, based on the conversion of outstanding shares of preferred stock into 17.1 million common shares immediately prior to the IPO's closing

Meanwhile, Gary Burgess, senior vice president of clinical research and chief medical officer, joined Conatus in 2011 from Pfizer, where he oversaw the assimilation of Idun, including data integration, clinical oversight of ongoing Phase II studies, development of clinical plans and registration strategies for emricasan...In all, emricasan has completed nine clinical studies, including some at Pfizer, enrolling more than 500 participants, according to Conatus

The compound is currently undergoing early stage clinical trials for the treatment of leukemia and solid tumor cancer, with rights to all oncology applications licensed to its partner, Eisai Co...Celgene has repurchased about $6.5 billion of its common stock over the last four years

Ironwood Pharmaceuticals Inc., of Cambridge, Mass., said underwriters of its public offering of Class A common stock have partially exercised their option to purchase an additional 704,948 shares at a public offering price of $13 apiece...Proceeds will be used to fund clinical trials, R&D for additional alpha-1 antitrypsin (AAT) indications, expanding distribution capabilities for additional territories for marketing AAT product Glassia and for general corporate purposes

The financing is expected to fund the lead program to clinical proof of concept for at least one hearing disorder indication. (See BioWorld Today, Aug. 23, 2011...The company issued approximately 11.5 million shares of common stock in connection with the warrant exercises

In its S-1, the company reported 18.4 million shares of common stock outstanding as of March 31...Since we're not going to have clinical data at the time we would expect the IPO – we're looking for funding to go into the clinic – the intent is that we try to produce as much preclinical data as we can," Harish said

Apricus Biosciences Inc., of San Diego, priced an underwritten public offering of 6 million shares of common stock at $2.85 per share and warrants to purchase up to an aggregate of 3 million shares of common stock, for proceeds of $17.1 million...The company said proceeds will be used for general corporate purposes, including clinical trial expenses and additional regulatory efforts related to erectile dysfunction drug Vitaros (alprostadil 0.3 percent topical cream) and female sexual dysfunction

Portola priced 8,422,758 shares of common stock at $14.50 per share, with a 30-day option for underwriters to purchase an additional 1,263,413 shares to cover overallotments...Stemline Therapeutics Inc., of New York, closed a public offering of 4,137,931 shares of common stock at $14.50 per share

Funds will be used to support ongoing and new clinical trials and development and commercialization of Parkinson's psychosis drug pimavanserin and for general corporate purposes...and to fund linaclotide development opportunities to strengthen the clinical profile of Linzess and expand the product label for additional populations and indications...Net proceeds are expected to total about $37.7 million and will be used to fund clinical trials of SFP, an iron compound for hemodialysis patients, and for

The company said it had 1.1 million shares of common stock outstanding as of May 15 and 14.2 million additional shares that would be issued upon the automatic conversion of outstanding shares of its preferred stock at the offering's close...The 2015 notes are convertible on or before June 14 into shares of the company's common stock at a price of about $48.83 per share (20.4794 shares per $1,000 principal amount

Proceeds will be used to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin, as well as activities for other product candidates and for general corporate purposes...Those personalized and targeted immunotherapies are aimed at providing significant and durable clinical benefit regardless of tumor origin, disease stage and prior treatments. (See BioWorld Today, Oct. 17, 2012...Receptos will use the proceeds to support clinical work in multiple sclerosis

Omeros Corp., of Seattle, said it closed the registered direct offering of 3.9 million shares of common stock priced at $4.14 per share, raising net proceeds of about $16.1 million...Funds will be used for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for R&D expenses such as funding planned clinical trials for its OMS103HP, PDE10, MASP-2 and PDE7 programs

Under the terms of its financing deal, Dyax priced a total of 8.9 million shares of common stock and 41,418 shares of Series 1 convertible preferred stock...MediciNova Inc., of San Diego, entered a securities purchase agreement, selling about 1.2 million shares of common stock priced at $3.15 apiece

Discovery Laboratories Inc., of Warrington, Pa., said it priced a $14.25 million public offering of 9.5 million shares of common stock at $1.50, an 8.5 percent discount to Thursday's closing price...Net proceeds are expected to total about $16.1 million and will be used for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for R&D expenses such as clinical trials of its OMS103HP, PDE10, MASP-2 and PDE7

In its filing, Isis said it would have 111.7 million shares of common stock outstanding when the offering closes...Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 months

Receptos Inc., of San Diego, priced its initial public offering (IPO) of 5.2 million shares of common stock at $14 per share, for a total raise of $72.8 million...The funds will support clinical work in multiple sclerosis (MS), inflammatory bowel disease (IBD) and allergic/immune-mediated disorders. (See BioWorld Today, April 8, 2013.) The pricing hits pretty close to the $86.3 million target set when the company filed for its offering only a month ago...Chardan Capital Markets LLC acted as exclusive

The drug has gone through 12 clinical trials in more than 1,400 subjects already, showing that it knocks down serum bile acid levels safely...Lumena plans to complete the Phase I clinical program of LUM002 in healthy volunteers later this year...Zalicus will control the timing and amount of any common stock sales to Lincoln Park.

The private placement of common stock and warrants to purchase common stock represents a final closing, which generated a total of $39.3 million, including $6.8 million from prior closings, The financing, the company expects, will fully fund the Phase III randomized, controlled study comparing CPX-351 for first-line therapy to conventional cytarabine and daunorubicin therapy (7 + 3) in patients, 60-75, with secondary acute myeloid leukemia (AML), with a primary endpoint of overall survival

The company plans to issue approximately 14.3 million shares of common stock and 9,900 shares of Series B convertible preferred stock at closing, expected on or about May 3...The preferred shares, priced at $1,000 apiece, may be converted into shares of common stock at a price of $1.83 per common stock share